Literature DB >> 1732420

The second chance for advanced Hodgkin's disease.

G P Canellos.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1732420     DOI： 10.1200/JCO.1992.10.2.175

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  [Role of high-dose chemotherapy in hematology and internal medicine/ oncology].

Authors:  A Engert; A Josting; M Reiser; D Söhngen; V Diehl
Journal:  Med Klin (Munich)       Date:  1999-08-15

2.  The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study.

Authors:  J M Raemaekers; G W van Imhoff; L F Verdonck; J A Hessels; W E Fibbe
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

3.  High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.

Authors:  N Schmitz; B Glass; P Dreger; T Haferlach; H A Horst; J Ollech-Chwoyka; M Suttorp; W Gassmann; H Löffler
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

4.  Phase-II trial with M-CAVe-CEC as a salvage chemotherapeutic regimen for early relapsed or primary refractory Hodgkin's disease.

Authors:  G Vreugdenhil; M Jongen-Lavrencic; J M Raemaekers; B E de Pauw
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

5.  Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

Authors:  R García; J M Hernández; M D Caballero; M González; J Galende; M C del Cañizo; L Vázquez; J F San Miguel
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.